Novel actions of inverse agonists on 5-HT2C receptor systems
- PMID: 10220565
Novel actions of inverse agonists on 5-HT2C receptor systems
Abstract
In cell systems where ligand-independent receptor activity is optimized (such as when receptors are overexpressed or mutated), acute treatment with inverse agonists reduces basal effector activity whereas prolonged exposure leads to sensitization of receptor systems and receptor up-regulation. Few studies, however, have reported effects of inverse agonists in systems where nonmutated receptors are expressed at relatively low density. Here, we investigated the effects of inverse agonists at human serotonin (5-HT)2C receptors expressed stably in Chinese hamster ovary cells ( approximately 250 fmol/mg protein). In these cells, there is no receptor reserve for 5-HT and 5-HT2C inverse agonists did not reduce basal inositol phosphate (IP) accumulation nor arachidonic acid (AA) release but behaved as simple competitive antagonists, suggesting that these receptors are not overexpressed. Prolonged treatment (24 h) with inverse agonists enhanced selectively 5-HT2C-mediated IP accumulation but not AA release. The enhancing effect occurred within 4 h of treatment, reversed within 3 to 4 h (after 24-h treatment), and could be blocked with neutral antagonists or weak positive agonists. The enhanced responsiveness was not due to receptor up-regulation but may involve changes in the expression of the G protein, Galphaq/11 and possibly Galpha12 and Galpha13. Interestingly, 24-h exposure to inverse agonists acting at 5-HT2C receptors also selectively enhanced IP accumulation, but not AA release, elicited by activation of endogenous purinergic receptors. These data suggest that actions of inverse agonists may be mediated through effects on receptor systems that are not direct targets for these drugs.
Similar articles
-
Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.Naunyn Schmiedebergs Arch Pharmacol. 2002 Mar;365(3):242-52. doi: 10.1007/s00210-001-0505-y. Epub 2002 Jan 16. Naunyn Schmiedebergs Arch Pharmacol. 2002. PMID: 11882920
-
Regulation of serotonin 5-HT2C receptors by chronic ligand exposure.Eur J Pharmacol. 2004 Sep 13;498(1-3):59-69. doi: 10.1016/j.ejphar.2004.07.102. Eur J Pharmacol. 2004. PMID: 15363976
-
Differences in agonist-independent and -dependent 5-hydroxytryptamine2C receptor-mediated cell division.Mol Pharmacol. 1996 Mar;49(3):474-80. Mol Pharmacol. 1996. PMID: 8643087
-
Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.Pharmacol Ther. 2009 Feb;121(2):160-73. doi: 10.1016/j.pharmthera.2008.10.010. Epub 2008 Dec 6. Pharmacol Ther. 2009. PMID: 19109993 Review.
-
Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.Trends Pharmacol Sci. 2005 Dec;26(12):625-30. doi: 10.1016/j.tips.2005.10.008. Epub 2005 Nov 2. Trends Pharmacol Sci. 2005. PMID: 16269190 Review.
Cited by
-
Signalling profile differences: paliperidone versus risperidone.Br J Pharmacol. 2013 Oct;170(3):532-45. doi: 10.1111/bph.12295. Br J Pharmacol. 2013. PMID: 23826915 Free PMC article.
-
Nucleus accumbens shell excitability is decreased by methamphetamine self-administration and increased by 5-HT2C receptor inverse agonism and agonism.Neuropharmacology. 2015 Feb;89:113-21. doi: 10.1016/j.neuropharm.2014.09.001. Epub 2014 Sep 16. Neuropharmacology. 2015. PMID: 25229719 Free PMC article.
-
Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model.Pulm Pharmacol Ther. 2008;21(1):115-24. doi: 10.1016/j.pupt.2007.06.003. Epub 2007 Jul 4. Pulm Pharmacol Ther. 2008. PMID: 17689122 Free PMC article.
-
Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation.Eur J Pharmacol. 2011 Dec 30;673(1-3):1-12. doi: 10.1016/j.ejphar.2011.10.006. Epub 2011 Oct 12. Eur J Pharmacol. 2011. PMID: 22020288 Free PMC article.
-
Similarities between the Binding Sites of SB-206553 at Serotonin Type 2 and Alpha7 Acetylcholine Nicotinic Receptors: Rationale for Its Polypharmacological Profile.PLoS One. 2015 Aug 5;10(8):e0134444. doi: 10.1371/journal.pone.0134444. eCollection 2015. PLoS One. 2015. PMID: 26244344 Free PMC article.